Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The role of ESAs agents in low-risk MDS

Claudio Cerchione • 10 Jun 2022
EHA 2022
Myelodysplastic Syndromes ESA

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, talks on the use of erythropoietin stimulating agents (ESAs) in low-risk myelodysplastic syndromes (MDS), commenting on the results of a real-world study that demonstrated that ESAs allowed patients to maintain a good quality of life (QoL). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Claudio Cerchione

6:48
Key trials in multiple myeloma presented at ASH 2023: take home messages
Claudio Cerchione • 11 Dec 2023
4:58
Novel immunotherapies transforming R/R myeloma treatment: bispecifics, CAR-T cells & more
Claudio Cerchione • 28 Sep 2023
3:15
Promising triplets and agents in R/R myeloma: SVd, Isa-Kd and melflufen
Claudio Cerchione • 28 Sep 2023
2:34
The role of FDG-PET plus whole body MRI in staging patients with high-risk SMM & R/R myeloma
Claudio Cerchione • 28 Sep 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals